Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-BN-CV301
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MVA-BN-CV301 is a cancer priming vaccine consisting of a proprietary version of the recombinant modified vaccinia Ankara-Bavarian Nordic (MVA-BN) viral vector. It encodes two human tumor-associated antigens, carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), along with the TRICOM costimulatory molecules (B7.1, ICAM-1, and LFA-3). The vaccine is used as a priming dose in a prime/boost regimen, followed by boosters of recombinant fowlpox virus (FPV-CV301). It is designed to stimulate an immune response against tumors expressing these antigens.
- Brand names
- CV301CV-301CV 301
- Other names
- CV301CV-301CV 301
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CD58 (Leukocyte function-associated antigen 3)ICAM1 (Intercellular Adhesion Molecule 1)MUC1 (Mucin-1 Antigen)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on MVA-BN-CV301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-BN-CV301.